WO2023086379A3 - Compositions et méthodes de reprogrammation de tcr à l'aide de protéines de fusion - Google Patents

Compositions et méthodes de reprogrammation de tcr à l'aide de protéines de fusion Download PDF

Info

Publication number
WO2023086379A3
WO2023086379A3 PCT/US2022/049396 US2022049396W WO2023086379A3 WO 2023086379 A3 WO2023086379 A3 WO 2023086379A3 US 2022049396 W US2022049396 W US 2022049396W WO 2023086379 A3 WO2023086379 A3 WO 2023086379A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
fusion proteins
compositions
tcr
tfps
Prior art date
Application number
PCT/US2022/049396
Other languages
English (en)
Other versions
WO2023086379A2 (fr
Inventor
Huan Yang
Jian Ding
Robert Hofmeister
Robert Tighe
Patrick Baeuerle
Original Assignee
TCR2 Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TCR2 Therapeutics Inc. filed Critical TCR2 Therapeutics Inc.
Publication of WO2023086379A2 publication Critical patent/WO2023086379A2/fr
Publication of WO2023086379A3 publication Critical patent/WO2023086379A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/464438—Tumor necrosis factors [TNF], CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/464468—Mesothelin [MSLN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des acides nucléiques recombinants comprenant une séquence codant pour des protéines de fusion (TFP) du récepteur des lymphocytes T (TCR) ayant une spécificité pour plus d'un antigène associé à une cellule tumorale, des lymphocytes T modifiés pour exprimer une ou plusieurs TFP, ainsi que des méthodes d'utilisation de ceux-ci pour le traitement de maladies, notamment du cancer.
PCT/US2022/049396 2021-11-10 2022-11-09 Compositions et méthodes de reprogrammation de tcr à l'aide de protéines de fusion WO2023086379A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163277938P 2021-11-10 2021-11-10
US63/277,938 2021-11-10

Publications (2)

Publication Number Publication Date
WO2023086379A2 WO2023086379A2 (fr) 2023-05-19
WO2023086379A3 true WO2023086379A3 (fr) 2023-08-10

Family

ID=86336720

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/049396 WO2023086379A2 (fr) 2021-11-10 2022-11-09 Compositions et méthodes de reprogrammation de tcr à l'aide de protéines de fusion

Country Status (1)

Country Link
WO (1) WO2023086379A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020088631A1 (fr) * 2018-11-01 2020-05-07 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions et procédés pour l'ingénierie des lymphocytes t
WO2021133959A2 (fr) * 2019-12-24 2021-07-01 TCR2 Therapeutics Inc. Compositions et procédés de reprogrammation de tcr gamma delta à l'aide de protéines de fusion
US11085021B2 (en) * 2016-10-07 2021-08-10 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
WO2021188599A1 (fr) * 2020-03-16 2021-09-23 University Of Southern California Nouveaux domaines de liaison à l'antigène et récepteurs d'antigènes synthétiques les incorporant

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11085021B2 (en) * 2016-10-07 2021-08-10 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
WO2020088631A1 (fr) * 2018-11-01 2020-05-07 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions et procédés pour l'ingénierie des lymphocytes t
WO2021133959A2 (fr) * 2019-12-24 2021-07-01 TCR2 Therapeutics Inc. Compositions et procédés de reprogrammation de tcr gamma delta à l'aide de protéines de fusion
WO2021188599A1 (fr) * 2020-03-16 2021-09-23 University Of Southern California Nouveaux domaines de liaison à l'antigène et récepteurs d'antigènes synthétiques les incorporant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATRICK A. BAEUERLE, DING JIAN, PATEL EKTA, THORAUSCH NIKO, HORTON HOLLY, GIERUT JESSICA, SCARFO IRENE, CHOUDHARY RASHMI, KINER OL: "Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response", NATURE COMMUNICATIONS, vol. 10, no. 1, 7 May 2019 (2019-05-07), XP055620180, DOI: 10.1038/s41467-019-10097-0 *

Also Published As

Publication number Publication date
WO2023086379A2 (fr) 2023-05-19

Similar Documents

Publication Publication Date Title
WO2019222275A3 (fr) Compositions et procédés de reprogrammation de tcr utilisant des protéines de fusion inductibles
MX2020009371A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión.
WO2018098365A3 (fr) Compositions et méthodes de reprogrammation de tcr au moyen de protéines de fusion
MX2020010459A (es) Metodos para producir celulas que expresan un receptor recombinante y composiciones relacionadas.
IL259120A (en) Her2-targeted antigen chimeric receptors2
MX2021001009A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión específicas de la diana.
WO2018073393A3 (fr) Cellules allogéniques modifiées par une nucléase d'effecteur tal (talen) appropriées pour une thérapie
WO2019002444A9 (fr) Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant
PH12020551039A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
CR20220136A (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
WO2021133959A3 (fr) Compositions et procédés de reprogrammation de tcr gamma delta à l'aide de protéines de fusion
AU2019343184A8 (en) Compositions and methods for treating cancer with anti-CD123 immunotherapy
EP3666793A3 (fr) Thérapie génique combinée liée au récepteur de lymphocytes t du cancer contre des épitopes restreints au cmh classe i ou classe ii de l'antigène tumoral ny-eso-1
WO2015075469A1 (fr) Cellule
MX2020010461A (es) Linfocitos t que expresan un receptor recombinante, polinucleotidos y metodos relacionados.
MX2021013219A (es) Celulas que expresan un receptor recombinante de un locus de tgfbr2 modificado, polinucleotidos relacionados y metodos.
FI3599251T3 (fi) Cd20-antigeeniin kohdentuvan kimeerisen antigeenireseptorin rakentaminen ja sillä muunnettujen t-solujen aktiivisuuden tunnistaminen
EA202190573A1 (ru) Композиции и способы перепрограммирования tcr с применением гибридных белков
JP7235391B2 (ja) 人工的に操作された免疫細胞
PH12020551134A1 (en) Fc variants with enhanced binding to fcrn and prolonged half-life
MX2021009357A (es) Dianas de genes de combinacion para mejorar la inmunoterapia.
MX2022013894A (es) Anticuerpos neutralizantes que se unen a la proteina s del sars-cov-2.
MX2022007107A (es) Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas.
WO2022081718A8 (fr) Anticorps anti-récepteur de chimiokine c-c 8 (ccr8) et leurs procédés d'utilisation
MX2022002984A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22893554

Country of ref document: EP

Kind code of ref document: A2